Sec. 107. IMPROVING ACCESS TO OVERDOSE TREATMENT
934 words·~4 min read·
/statute-compilations/comps-12178/sec-107A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
## SEC. 107 IMPROVING ACCESS TO OVERDOSE TREATMENT ### (a)2 Grants for Reducing Overdose Deaths Part D of title V of the Public Health Service Act (42 U.S.C. 290dd et seq.) is amended by adding at the end the following: 2Section 1219(a)(7)(B) of division FF of Public Law 117-328 provides for an amendment to strike subsection
(b)of section 107 which results in this section having a subsection
(a)in law without there being any subsequent subsections. > > ## “SEC. 544 GRANTS FOR REDUCING OVERDOSE DEATHS > > **[**[42 U.S.C. 290dd-3](/us/usc/t42/s290dd-3)**]** > > > ### “(a) Establishment > > > #### “(1) In general > > The Secretary shall award grants to eligible entities to expand access to drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose. > > > #### “(2) Maximum grant amount > > A grant awarded under this section may not be for more than $200,000 per grant year. > > > #### “(3) Eligible entity > > For purposes of this section, the term ‘eligible entity’ means a Federally qualified health center (as defined in section 1861(aa) of the Social Security Act), an opioid treatment program under part 8 of title 42, Code of Federal Regulations, any practitioner dispensing narcotic drugs pursuant to section 303(g) of the Controlled Substances Act, or any other entity that the Secretary deems appropriate. > > > #### “(4) Prescribing > > For purposes of this section, the term ‘prescribing’ means, with respect to a drug or device approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose, the practice of prescribing such drug or device— > > > ##### “(A) > > in conjunction with an opioid prescription for patients at an elevated risk of overdose; > > > ##### “(B) > > in conjunction with an opioid agonist approved under section 505 of the Federal Food, Drug, and Cosmetic Act for the treatment of opioid use disorder; > > > ##### “(C) > > to the caregiver or a close relative of patients at an elevated risk of overdose from opioids; or > > > ##### “(D) > > in other circumstances in which a provider identifies a patient is at an elevated risk for an intentional or unintentional drug overdose from heroin or prescription opioid therapies. > > > ### “(b) Application > > To be eligible to receive a grant under this section, an eligible entity shall submit to the Secretary, in such form and manner as specified by the Secretary, an application that describes— > > > #### “(1) > > the extent to which the area to which the entity will furnish services through use of the grant is experiencing significant morbidity and mortality caused by opioid abuse; > > > #### “(2) > > the criteria that will be used to identify eligible patients to participate in such program; and > > > #### “(3) > > a plan for sustaining the program after Federal support for the program has ended. > > > ### “(c) Use of Funds > > An eligible entity receiving a grant under this section may use amounts under the grant for any of the following activities, but may use not more than 20 percent of the grant funds for activities described in paragraphs
(3)and (4): > > > #### “(1) > > To establish a program for prescribing a drug or device approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose. > > > #### “(2) > > To train and provide resources for health care providers and pharmacists on the prescribing of drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose. > > > #### “(3) > > To purchase drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose, for distribution under the program described in paragraph (1). > > > #### “(4) > > To offset the co-payments and other cost sharing associated with drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose. > > > #### “(5) > > To establish protocols to connect patients who have experienced a drug overdose with appropriate treatment, including medication-assisted treatment and appropriate counseling and behavioral therapies. > > > ### “(d) Evaluations by Recipients > > As a condition of receipt of a grant under this section, an eligible entity shall, for each year for which the grant is received, submit to the Secretary an evaluation of activities funded by the grant which contains such information as the Secretary may reasonably require. > > > ### “(e) Reports by the Secretary > > Not later than 5 years after the date on which the first grant under this section is awarded, the Secretary shall submit to the appropriate committees of the House of Representatives and of the Senate a report aggregating the information received from the grant recipients for such year under subsection
(d)and evaluating the outcomes achieved by the programs funded by grants awarded under this section. > > > ### “(f) Authorization of Appropriations > > There is authorized to be appropriated to carry out this section, $5,000,000 for the period of fiscal years 2017 through 2021.” > .
Connectionstraces to 3
Traces to 3 documents
Citation graph
cites case law
Cites 3Cited by 0 across 0 sources